Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients

PURPOSE: UGT1A1*28 confers a higher risk of toxicity in patients treated with irinotecan. Patients with *1/*1 and *1/*28 genotypes might tolerate higher than standard doses of irinotecan. We aimed to identify the maximum tolerated dose (MTD) of irinotecan in mCRC patients with *1/*1 and *1/*28 genot...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Toffoli, Giuseppe, Sharma, Manish R., Marangon, Elena, Posocco, Bianca, Gray, Elizabeth, Mai, Quan, Buonadonna, Angela, Polite, Blase N., Miolo, Gianmaria, Tabaro, Gianna, Innocenti, Federico
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777349/
https://ncbi.nlm.nih.gov/pubmed/27507617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1012
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky